GO:0001552 ovarian follicle atresia: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001552 ovarian follicle atresia is the periodic degeneration and re-absorption of immature ovarian follicles, a process that determines the size of the ovarian reserve and reproductive lifespan.
• Atresia is driven by an imbalance between survival and death signals, including gonadotropins, intra-ovarian growth factors, and apoptotic pathways.
• Follicle atresia occurs at all stages of follicular development, from primordial to antral follicles, and can be triggered by physiological or toxic stimuli.
• Key regulators include WIP1 (PPM1D), which protects against atresia; low WIP1 expression accelerates ovarian aging by promoting follicular atresia and primordial follicle activation.
• Histological and genomic studies in cattle have identified breed- and production-related differences in atresia and follicle growth regulation.
• Experimental models for atresia research include knockout, point-mutation, knock-in, and overexpression cell and animal models, which can be generated using CRISPR gene editing.
Description
Ovarian follicle atresia (GO:0001552) is a fundamental biological process in which immature ovarian follicles degenerate and are subsequently re-absorbed. This process is periodic and occurs throughout reproductive life, contributing to the depletion of the ovarian reserve and the timing of reproductive senescence. Understanding atresia is critical for reproductive biology, as it directly influences fertility, response to gonadotropins, and the impact of environmental or therapeutic insults on the ovary.
ovarian follicle atresia At A Glance
| GO ID | GO:0001552 |
|---|---|
| GO term | ovarian follicle atresia |
| Ontology | biological_process |
| Synonym | none |
| Major function | Degeneration and re-absorption of immature ovarian follicles |
| Process type | Periodic, physiological and pathological |
| Cellular context | Ovarian follicle (granulosa cells, oocyte, theca cells) |
| Regulatory signals | Gonadotropins, intra-ovarian growth factors, apoptotic pathways |
| Research relevance | Ovarian aging, fertility, reproductive toxicology |
What Is GO:0001552?
According to the Gene Ontology, ovarian follicle atresia (GO:0001552) is a periodic process in which immature ovarian follicles degenerate and are subsequently re-absorbed. This definition encompasses the regulated elimination of follicles at various developmental stages, distinct from ovulation or luteinization.
Why Is ovarian follicle atresia Important in Cell Biology?
Ovarian follicle atresia is a central determinant of the ovarian reserve and reproductive lifespan, and its dysregulation is implicated in premature ovarian insufficiency, infertility, and the ovarian toxicity of chemotherapeutic agents. Studying atresia provides insights into the balance between follicle survival and death, which is essential for developing fertility preservation strategies and understanding ovarian aging.
• Regulates the size of the ovarian reserve and timing of reproductive senescence.
• Influences fertility and response to assisted reproductive technologies.
• Mediates ovarian toxicity of drugs such as doxorubicin, which obliterates the ovarian reserve through primordial follicle atresia and overactivation.
• Involved in ovarian aging; low WIP1 expression accelerates aging by promoting follicular atresia.
• Affects livestock reproduction, as shown by histological and genomic studies in dairy cows.
• Provides a model for studying apoptosis and survival signaling in a physiological context.
• Relevant to reproductive toxicology and drug safety assessment.
• Potential target for interventions to preserve fertility during cancer treatment.
What Happens During ovarian follicle atresia?
Initiation of atresia
In simple terms: Atresia begins when a follicle receives signals that trigger its degeneration.
Atresia can be initiated at any stage of follicular development, from primordial to antral follicles, and is characterized by morphological changes such as granulosa cell apoptosis and oocyte degeneration. The process is periodic and can be influenced by hormonal and local factors.
Apoptotic and survival signaling
In simple terms: The fate of a follicle depends on a balance between signals that promote cell death and those that promote survival.
Growth factors and gonadotropins play key roles in regulating follicle atresia; a delicate balance between life and death signals determines whether a follicle survives or undergoes atresia. Apoptosis of granulosa cells is a hallmark of atresia, and survival factors such as IGF-1 and EGF can suppress this process.
Role of WIP1 and other regulators
In simple terms: Certain proteins act as brakes on atresia; when they are reduced, atresia accelerates.
WIP1 (PPM1D) is a phosphatase that protects follicles from atresia; low WIP1 expression accelerates ovarian aging by promoting follicular atresia and primordial follicle activation. This highlights the importance of specific molecular regulators in controlling the rate of atresia.
Histological and genomic features
In simple terms: Atresia can be observed under the microscope and is associated with changes in gene expression.
Histological studies in dairy cows have characterized atresia in follicles and shown differences related to milk production. Genomic analyses have revealed breed-specific patterns of follicle growth regulation, including genes involved in atresia.
Re-absorption of degenerated follicles
In simple terms: After degeneration, the remnants of the follicle are cleared away by the body.
Following degeneration, the follicle is re-absorbed, a process that involves phagocytosis by ovarian macrophages and other cells. This clearance is essential for maintaining ovarian tissue homeostasis.
Key Genes Involved in GO:0001552 ovarian follicle atresia
The following genes and proteins have been implicated in the regulation of ovarian follicle atresia based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPM1D (WIP1) | Phosphatase that protects follicles from atresia | Low expression accelerates ovarian aging and atresia |
| IGF1 | Growth factor that promotes follicle survival | Suppresses atresia in cultured follicles |
| EGF | Growth factor that promotes survival | Inhibits atresia in vitro |
| FSHR | Receptor for FSH, mediates gonadotropin signals | Essential for follicle survival and development |
| LHCGR | Receptor for LH, involved in ovulation and luteinization | May influence atresia of antral follicles |
| CASP3 | Executioner caspase in apoptosis | Mediates granulosa cell apoptosis during atresia |
| BAX | Pro-apoptotic Bcl-2 family member | Promotes atresia |
| BCL2 | Anti-apoptotic protein | Inhibits atresia |
| TP53 | Tumor suppressor, regulates apoptosis | May be involved in stress-induced atresia |
| BMP15 | Oocyte-derived growth factor | Regulates granulosa cell proliferation and atresia |
| GDF9 | Oocyte-derived growth factor | Promotes follicle growth and inhibits atresia |
| AMH | Inhibits primordial follicle activation | Marker of ovarian reserve; may influence atresia |
| FOXO3 | Transcription factor involved in apoptosis | Mediates atresia in response to stress |
| AKT1 | Survival kinase | Promotes follicle survival |
| MTOR | Central regulator of cell growth and survival | May modulate atresia |
| CASP8 | Initiator caspase in extrinsic apoptosis | Contributes to atresia |
| CASP9 | Initiator caspase in intrinsic apoptosis | Contributes to atresia |
How Is ovarian follicle atresia Regulated?
Ovarian follicle atresia is regulated by a complex interplay of endocrine and paracrine signals. Gonadotropins, particularly FSH and LH, promote follicle survival, while withdrawal of these hormones can trigger atresia. Intra-ovarian growth factors such as IGF-1, EGF, BMP15, and GDF9 modulate the balance between survival and apoptosis. Additionally, the phosphatase WIP1 (PPM1D) acts as a negative regulator of atresia, and its downregulation accelerates ovarian aging. The process is also influenced by apoptotic pathways involving Bcl-2 family proteins and caspases.
ovarian follicle atresia and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPM1D (WIP1) | Premature ovarian insufficiency / ovarian aging | WIP1 knockout or overexpression in mouse granulosa cells |
| CASP3 | Infertility due to excessive atresia | Casp3 knockout mouse model |
| BAX | Ovarian reserve depletion | Bax knockout mouse |
| FSHR | Ovarian dysgenesis / infertility | Fshr knockout mouse |
| TP53 | Chemotherapy-induced ovarian damage | Trp53 knockout mouse treated with doxorubicin |
Premature ovarian insufficiency and infertility
Accelerated follicle atresia contributes to premature ovarian insufficiency and infertility, as it depletes the ovarian reserve prematurely. Low WIP1 expression is associated with accelerated ovarian aging and increased atresia.
Ovarian toxicity of chemotherapy
Chemotherapeutic agents such as doxorubicin can obliterate the ovarian reserve by inducing primordial follicle atresia and overactivation, leading to infertility in cancer survivors.
Reproductive aging and livestock fertility
Atresia is a key process in reproductive aging, and in dairy cows, histological and genomic studies have linked atresia to fertility and milk production traits.
From ovarian follicle atresia-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X protect against atresia? | Knockout of gene X in mouse granulosa cells or ovaries |
| Does a point mutation in gene X affect atresia? | Point-mutation knock-in mouse model |
| Does overexpression of gene X inhibit atresia? | Transgenic overexpression in mouse oocytes or granulosa cells |
| Does gene X interact with apoptotic machinery? | Tagged knock-in for co-immunoprecipitation |
| Does gene X regulate primordial follicle activation? | Conditional knockout in oocytes |
| Does gene X mediate chemotherapy-induced atresia? | Knockout mouse treated with doxorubicin |
How to Study the ovarian follicle atresia Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Histology (H&E) | Morphology of follicles | Detection of atretic follicles |
| TUNEL assay | Apoptotic DNA fragmentation | Quantification of granulosa cell apoptosis |
| RNA-seq | Global gene expression | Identification of pathways involved in atresia |
| qPCR | Expression of specific genes | Validation of candidate genes |
| Western blot | Protein levels and modifications | Analysis of apoptotic markers |
| Immunohistochemistry | Protein localization in tissue | Detection of WIP1 or caspases in follicles |
| Flow cytometry | Cell viability and apoptosis | Analysis of granulosa cells |
Histological analysis
Histological examination of ovarian sections allows the identification and quantification of atretic follicles based on morphological criteria such as granulosa cell apoptosis and oocyte degeneration.
RNA sequencing and transcriptomics
RNA-seq can reveal gene expression changes associated with atresia, identifying pathways and candidate regulators.
Apoptosis assays
TUNEL staining, caspase activity assays, and flow cytometry are used to detect apoptosis in granulosa cells during atresia.
Genomic and bioinformatic analyses
Genomic studies, such as those in cattle, integrate gene expression and genomic data to identify regulatory networks controlling follicle growth and atresia.
How CRISPR Can Be Used to Study GO:0001552 ovarian follicle atresia
Knockout
CRISPR knockout of candidate genes such as PPM1D or CASP3 in granulosa cell lines or mouse models can determine their causal role in atresia.
Point Mutation
Introducing point mutations in genes like FSHR or TP53 can mimic human variants and assess their impact on follicle survival and atresia.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-WIP1) allows live-cell imaging and interaction studies in follicles.
Overexpression
Overexpression of survival factors such as IGF1 or BCL2 using CRISPR activation or transgenic approaches can test their ability to suppress atresia.
How EDITGENE Supports ovarian follicle atresia Research
Researchers studying ovarian follicle atresia-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for ovarian follicle atresia research.
Frequently Asked Questions About ovarian follicle atresia
What is ovarian follicle atresia?
Ovarian follicle atresia (GO:0001552) is a periodic process in which immature ovarian follicles degenerate and are subsequently re-absorbed.
What genes are involved in ovarian follicle atresia?
Key genes include PPM1D (WIP1), IGF1, EGF, CASP3, BAX, BCL2, FSHR, and others involved in survival and apoptotic signaling.
How is ovarian follicle atresia regulated?
It is regulated by a balance of gonadotropins, intra-ovarian growth factors, and apoptotic pathways.
What is the role of WIP1 in atresia?
WIP1 (PPM1D) protects follicles from atresia; low WIP1 expression accelerates ovarian aging by promoting follicular atresia.
Can chemotherapy cause ovarian follicle atresia?
Yes, doxorubicin can obliterate the mouse ovarian reserve through primordial follicle atresia and overactivation.
How do researchers study ovarian follicle atresia?
Methods include histology, TUNEL assay, RNA-seq, and CRISPR knockout models.
What is the difference between atresia and ovulation?
Atresia is degeneration of follicles, while ovulation is the release of a mature oocyte; both are outcomes of follicular development.
Is ovarian follicle atresia conserved across species?
Yes, it occurs in mammals including mice, cows, and humans, though details may vary.
What are the histological features of atresia?
Atretic follicles show granulosa cell apoptosis, oocyte degeneration, and subsequent re-absorption.
How can CRISPR help study atresia?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional testing of candidate genes in atresia.
Conclusion
Ovarian follicle atresia (GO:0001552) is a critical process that shapes the ovarian reserve and reproductive lifespan. Its dysregulation contributes to infertility, premature ovarian insufficiency, and ovarian toxicity. Continued research using advanced CRISPR models and genomic approaches will further elucidate the molecular mechanisms and identify therapeutic targets.
References
- 1. McGee EA et al.. 2000. Initial and cyclic recruitment of ovarian follicles.. Endocr Rev 21(2):200-14 PMID: 10782364
- 2. Craig J et al.. 2007. Gonadotropin and intra-ovarian signals regulating follicle development and atresia: the delicate balance between life and death.. Front Biosci 12:3628-39 PMID: 17485326
- 3. Wang Y et al.. 2019. Doxorubicin obliterates mouse ovarian reserve through both primordial follicle atresia and overactivation.. Toxicol Appl Pharmacol 381:114714 PMID: 31437492
- 4. Crisp TM. 1992. Organization of the ovarian follicle and events in its biology: oogenesis, ovulation or atresia.. Mutat Res 296(1-2):89-106 PMID: 1279410
- 5. Zhou S et al.. 2022. Low WIP1 Expression Accelerates Ovarian Aging by Promoting Follicular Atresia and Primordial Follicle Activation.. Cells 11(23) PMID: 36497179
- 6. Makarevich AV et al.. 2018. Histological characteristics of ovarian follicle atresia in dairy cows with different milk production.. Anat Histol Embryol 47(6):510-516 PMID: 30022512
- 7. Chun SY et al.. 1996. Growth factors in ovarian follicle atresia.. Semin Reprod Endocrinol 14(3):197-202 PMID: 8885050
- 8. Zielak-Steciwko AE et al.. 2016. Genomic portrait of ovarian follicle growth regulation in cattle.. Reprod Biol 16(3):197-202 PMID: 27460518
